Direct SARS-CoV-2 infection of the heart potentiates the cardiovascular sequelae of COVID-19

Drug Discov Today. 2020 Sep;25(9):1559-1560. doi: 10.1016/j.drudis.2020.06.021. Epub 2020 Jun 24.
No abstract available

Publication types

  • Editorial
  • Research Support, N.I.H., Extramural
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Angiotensin-Converting Enzyme 2
  • Antiviral Agents / pharmacology*
  • Betacoronavirus* / drug effects
  • Betacoronavirus* / pathogenicity
  • Betacoronavirus* / physiology
  • COVID-19
  • Coronavirus Infections* / drug therapy
  • Coronavirus Infections* / metabolism
  • Coronavirus Infections* / physiopathology
  • Coronavirus Infections* / prevention & control
  • Drug Development / methods
  • Drug Development / trends
  • Enzyme Inhibitors / pharmacology
  • Heart* / drug effects
  • Heart* / physiopathology
  • Heart* / virology
  • Humans
  • Myocarditis* / metabolism
  • Myocarditis* / physiopathology
  • Myocarditis* / prevention & control
  • Myocarditis* / virology
  • Myocytes, Cardiac* / physiology
  • Myocytes, Cardiac* / virology
  • Pandemics* / prevention & control
  • Peptidyl-Dipeptidase A / metabolism
  • Pneumonia, Viral* / drug therapy
  • Pneumonia, Viral* / metabolism
  • Pneumonia, Viral* / physiopathology
  • Pneumonia, Viral* / prevention & control
  • SARS-CoV-2
  • Virus Internalization / drug effects

Substances

  • Antiviral Agents
  • Enzyme Inhibitors
  • Peptidyl-Dipeptidase A
  • ACE2 protein, human
  • Angiotensin-Converting Enzyme 2